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Dr Frederick P. Beavers (Washington, DC). I have a couple
of questions, but before I ask them I’d like to preface those
questions by the following comments.
Recently in the lay press, there have been questions as to
whether the medical community as well as the pharmaceutical
industry, is developing new diagnoses. Some of those listed are
prehypertension, erectile dysfunction, and restless leg syndrome.
And one of these may be metabolic syndrome.
My questions to you are the following: reviewing the meta-
bolic syndrome criteria, it appears that 31% of the patients reviewed
had a metabolic syndrome; 38% fell short, only having 2 of the 5
required criteria. Did you do an analysis to see if there was any
difference between the two groups?
The second question is, did you think it wise to include or
group the carotid endarterectomy and the carotid artery angio-
plasty groups into this study given the controversies as to whether
these are equivalent therapies or one has a higher morbidity and
mortality risk?
Dr Protack. In answer to your first question, we did not
analyze our data based on whether a patient had 1, 2, 3, 4, or 5 of
the factors present, and see if the number of factors correlated.
In answer to your second question we chose to look at the
entire population as this was retrospective and we presumed was
the best practice during the period. However, in the paper we did
look at subgroups based on intervention: in those patients who
underwent carotid endarterectomy, there were differences be-
tween patients with and without metabolic syndrome; similarly
there were differences between patients with and without meta-
bolic syndrome that received carotid stents.
Dr Karl Illig (Rochester, NY). Do you think metabolic
syndrome is a real entity or is it just one end of the bell-shapedDr Protack.Metabolic syndrome is considered a real entity by
most in academic health care and public policy has been adapted to
develop intervention strategies to combat the individual elements.
Dr Brajesh Lal (Newark, NJ). I think the true answer is that
metabolic syndrome is just a collection of risks factors that you’ve
decided to give a name – hypertension, diabetes, hyperlipidemia.
What you’ve really done statistically, is eliminate carotid stent-
ing and endarterectomy from the picture. You have identified a
group of patients that were sick and therefore they died or had an
MI. If they were sicker, more would die or have an MI. And if they
were the sickest group, even more would die and have an MI.
So my question to you is, what does carotid endarterectomy
and stenting have to do at all with your results? What you’ve
proven to me is that metabolic syndrome is a risk factor for MI and
death.
Dr Protack. The definitions of metabolic syndrome is not
ours but is that of the major medical professional and health policy
organizations. I agree that metabolic syndrome groups the various
risk factors together but the consensus of opinion is that this leads
to synergy and potentially greater risk than the aggregate of the
individual risk factors. In this study, we saw an increase in stroke
which is one of the principal outcomes measures for carotid inter-
ventions, and so is important for vascular surgeons to know and
understand in the context of carotid disease.
Dr Martin Back (Tampa, Fla). For clarity of discussion,
metabolic syndrome was not a marker for long-term survival or
death. It was a marker for late MI. Periprocedurally there was a
higher rate of stroke in patients with metabolic syndrome. And you
said, to clarify Dr Beavers’ point, that stroke was more common in
patients with metabolic syndrome who underwent carotid stenting
as well as carotid endarterectomy. Is that correct?Dr Protack. Yes, that is correct.
